安盛生科股份有限公司安盛生科 – 行動醫療科技的先驅。
我們將智慧型手機化為實驗室等級的醫療檢測儀器，提供醫療專業人員用於定點照護和消費者居家自我檢測。安盛生科的安必測血糖監測系統(PixoTest® Blood Glucose Monitoring System) 2017年通過美國FDA核准，成為世界第一個以行動裝置相機獲此認證的血液檢測產品。
安盛生科的創辦團隊結識於美國史丹佛大學，2011年看到智慧型手機全球普及規模、數位醫療的興起，以及兩者能夠改造未來醫療的無限潛力。安盛生科於2012年在美國矽谷創立，隨後在台北註冊成立。我們的團隊整合醫學工程、生物化學和資訊科技的專業研發實力，共同打造出創新的數位醫療解決方案。
安盛生科已獲得超過70項國際專利保護的PixoTech® 技術平台為軸心，發展出婦女健康、慢性疾病和傳染性疾病等產品線。以PixoTech® 技術平台延伸的醫療檢測開發授權商業模式，將是我們下一階段成長的關鍵引擎。
我們的創新不但榮獲許多國際獎項肯定，也獲選加入多項國際醫療科技加速器計畫，保括Merck、Plug & Play’s Startup Creasphere，並於2020年進駐上海Johnson & Johnson Innovation (強生創新) JLABS。在2022年, 我們授權PixoTech®給Rhoto日本樂敦製藥，並同時獲得其策略投資。
iXensor - The pioneer of mobile health.
We turn ordinary smartphones into versatile lab-grade medical diagnostic devices for point-of-care testing and at-home self-testing solutions. PixoTest®, our first product, is also the world’s first FDA approved smartphone camera-based blood test dated back in 2017.
The founding team of iXensor first met at Stanford University in 2011. At that time, they saw the rise of the smartphone and its potential to reshape future healthcare. In 2012, iXensor was founded in Silicon Valley and then incorporated in Taipei, Taiwan. Our interdisciplinary team combines expertise in medical engineering, biochemistry, and information technology to develop innovative digital health solutions that empower tomorrow’s connected healthcare.
Our product lines cover Women’s Health, Chronic, and Infectious Diseases and are powered by our core technology – PixoTech® platform protected by more than 70 international patents. PixoTech® serves as the platform-as-a-service model and will be the engine for our next phase of growth.
We have received many international awards for our innovation, and our business has also been accelerated by Merck Accelerator, Plug & Play’s Creasphere, and Johnson & Johnson Innovation’s JLABs. In 2022, we successfully licensed out PixoTech® to Rhoto Pharmaceutical and received its strategic investment.